The hemostatic efficacy of Esperoct® was assessed in 33 patients with hemophilia A who underwent 45 major surgeries.1,a
EFFICACY IN MAJOR SURGERIES
aA phase 3, open-label, nonrandomized trial to assess the hemostatic efficacy of Esperoct® during major surgery in 33 patients with hemophilia A who underwent 45 major surgeries, 41 of which were orthopedic (15 joint replacements, 9 arthroscopic orthopedic interventions, and 17 classified as “other” orthopedic interventions). The success rate in bleed control during surgery was evaluated on a 4-point scale of excellent, good, moderate, or poor. Treatment success was defined as excellent or good bleed control.1,2
SIMPLE PERIOPERATIVE DOSING.1
No need to calculate desired FIX activity levels to determine the appropriate dose.
bPerioperative dosing recommendation for pediatric patients is 65 IU/kg.1
cFor minor surgeries, additional dose(s) can be administered after 24 hours; for major surgeries, additional doses can be administered every 24 hours in the first week and then every 48 hours in the second week.1